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This is a growing burden of cardiometabolic disease in many parts of the world. Despite some 
progress in their prevention, more can be done to tackle risks of their development in the community 
and in different speciality clinics. Currently, the identification and management of those at elevated 
risk of developing cardiovascular disease, diabetes, or with conditions such fatty liver disease remains 
fragmented, and is not linked to constructive lifestyle advice. In this Perspective, we argue for a more 
consistent weight management approach, alongside a holistic assessment of risk for developing 
cardiometabolic diseases, offering patients a range of simple or more intensive evidence-based 
options in an empathetic manner with encouragement for repeated attempts and a willingness to 
embrace failure.  
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Introduction 
 
Over the last 3-4 decades, considerable progress in the prevention and treatment of cardiovascular 
diseases (CVD) has been made. The major causal risk factors of these diseases are smoking, high 
cholesterol and high blood pressure and the rates or incidence of these has declined over the last 
several decades1 in most high-income countries. The result has been a remarkable decline in 
cardiovascular disease-induced deaths such that more people in high income countries now die from 
cancer than cardiovascular disease2. However, at the same time obesity rates have escalated markedly 
over the last few decades3 as has the prevalence of type 2 diabetes4. This increase in type 2 diabetes is 
linked variably in different parts of the world to rising rates of obesity, aging populations as well as 
more testing for glycaemia leading to fewer undiagnosed cases.  
 
This changing pattern of disease presents substantial challenges to health care; it should serve as a call 
to improve prevention of cardiovascular disease by better targeting those at risk. At the same time, 
there is a need to improve advice on lifestyle changes in clinical care such that the medical profession 
offers individuals a range of simple evidenced-based options towards sustainable lifestyle changes. 
Such lifestyle changes can lessen risks for several cardiometabolic diseases, including cardiovascular 
diseases, diabetes and non-alcoholic fatty liver disease, plus potentially some cancers, as well as 
improve quality of life. Of course, public health strategies can have major benefits in reducing 
populations’ risks for cardiometabolic diseases by, for example, taxing sugar-rich drinks or related 
measures but such issues are beyond the scope of this article. We present below a summary of the 
medical challenges towards more holistic testing for risks and in introducing lifestyle interventions as 
well as a list of potential options to help address these.  
 
Trends in cardiovascular and diabetes prevalence \ 
It is now not disputed that smoking, high blood pressure and high blood lipid levels (cholesterol more 
strongly than triglyceride) are causal risk factors for CVD. Multiple guidelines around the world now 
place great emphasis on measuring these risk factors in people when they attend for care in either 
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primary practice or their secondary health care providers5. However, it remains debated at what age 
apparently healthy people are best screened and how to carry out this screening efficiently with 
respect to time and resources. Some recent advances in risk screening have helped to simplify the 
process (Box 1). There remains a need, however, to better identify individuals at higher risk of 
developing CVD and metabolic complications. Furthermore, current intervention strategies are not 
impacting the rising obesity rates and its associated effects on disease risk and quality of life. The 
recent trend in high income countries of reducing CVD death rates may soon be reversed by societal 
adiposity shifts, as obesity is causally linked to many cardiovascular diseases.6 To identify those at 
risk requires more opportunities for individuals to be tested along with providing individuals with 
better education on the risk factors for CVD and diabetes and how to mitigate them.  
 
In high-income countries, robust advances have also been made in diabetes management; CVD 
hospitalisations and CVD death rates in those with diabetes have come down over the last few 
decades broadly commensurate with trends in the general population, though more can be done to 
lower the associated risks of disease in diabetes.7 Concerns going forwards include more younger 
people developing type 2 diabetes; in high income countries, such individuals are more often severely 
obese and their glucose levels rise faster over time compared with those who develop diabetes much 
later in life.8,9 Furthermore, the rising number of people with type 2 diabetes in general is stretching 
health services; part of this is due to better survival of people with diabetes in high income countries. 
This pattern is also extending comorbidity levels in diabetes, as less premature deaths due to CVD 
causes means patients have more time to develop other diabetes complications .10  
 
There is, however, good news with better management strategies at different stages of diabetes.  
Recent trials have revealed classes of diabetes drugs such as SGLT2 inhibitors, drugs which enhance 
urinary excretion of sugar, salt and water, and GLP-1RA, drugs which help improve the release of 
insulin after meals and aid weight loss, that lessen a range of hard cardiovascular and cardiorenal 
outcomes in those with diabetes and existing cardiovascular diseases. 11,12. As these new classes of 
drugs are considerably more expensive than some of the more established anti-hyperglycaemia 
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medicines, the challenge is how to optimise their use in a cost-effective manner.  At the same time, 
there has been progress in diabetes prevention. Early examination of the English diabetes prevention 
programme shows good weight loss in individuals adhering to the programme but improvements in 
program engagement, retention and completion are required13. Currently, the focus of these 
programmes is to identify those at highest risk and introduce lifestyle changes to slow or halt 
progression to diabetes. However, as the pre-diabetes population has on average a higher prevalence 
of hypertension, obesity and dyslipidaemia, those identified at high risk of diabetes would also benefit 
from formal assessment of their CV risk14. Thus, going forwards, there is merit in discussing how best 
to screen relevant people for both CVD and diabetes risks.15  Official guidance would help target 
blood tests to those at higher risk.  
 
Developing effective screening  
Screening for cardiometabolic conditions and their associated risks is often done initially by trained 
allied health professionals in primary care to save on time and costs. Nurses or other trained staff can 
collect routine weight, height and blood pressure and ask some simple questions on smoking, alcohol 
intake and family history of CVD and T2DM. All the collected information could be entered into one 
combined risk scoring system that simultaneously reads out separate non-laboratory-based risk 
estimates for both conditions. This is possible since several risk parameters such as age, sex, BMI, 
blood pressure, and socioeconomic status predict both conditions, even if their magnitudes of 
association differ, in some cases markedly (e.g. higher BMI is much more strongly linked to risk for 
diabetes than to risk for CVD16). Such a risk score could help inform which people warrant further 
formal blood tests to analyse in more detail their risk. For those at risk of CVD: blood test for non-
fasting lipids, liver biochemistry and kidney function tests would be actioned. For those at risk of 
diabetes: glycated haemoglobin [HbA1c], a test of average sugar level over the last two to three 
months, or fasting glucose if patients fasted, are easy additions. For simplicity, doctors might wish to 
run all tests to be comprehensive (Figure 1), though laboratory costs and workload of conducting 
such tests are not insignificant. 
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The potential advantages and challenges to screening 
Initial risk scoring is not difficult and with education could be done relatively quickly by allied health 
professionals. It could also be done in a range of non-clinical settings where people often attend to 
make initial checks more accessible. A recent example is the community based screening for diabetes 
in barbershops to identify black men with undiagnosed diabetes17. Since many people tested will be at 
low absolute risk for both CVD and diabetes, only a minority at higher or intermediate risk (or those 
with a family history of premature cardiovascular disease) would require formal blood testing. From 
this latter group, a further subgroup would warrant potential therapy or specific advice to be delivered 
by doctors. As age is a major risk factor for both conditions, blood tests would be more commonly 
done in those in middle and older age, and some guidelines advocate risk screening or CVD above 40 
or 50 years of age. In the younger groups, those found to be at lower risk could be rescreened in 3-5 
years, with perhaps more frequent rescreening in older groups. 
 
There are of course multiple challenges to widening health checks as has been seen with the English 
Vascular Health checks programme that has low coverage and poor statin prescription in high risk 
individuals18. Notably, fewer people from socioeconomically deprived or black and minority ethnic 
communities attend these checks in the UK. Thus, widening access to health checks in pharmacies 
and other local places (e.g. community centres, places of worship, barbershops etc.) in the UK or 
elsewhere could help as could a well thought out, empathic public communication programmes to 
highlight the benefits of a simple and quick risk assessment and of simple lifestyle advice. Whilst 
prior trials have not shown outcome benefits from nationwide screening programmes, at least over 10 
years19 (longer follow-up may be needed), the evidence base on how to help people make lifestyle 
improvements has improved and the cost-effectiveness of some preventative (lipid-lowering, 
antihypertensive) treatments has also increased as drug costs have declined20,21. The medical 
profession is also slowly improving its communication of risk so that people can better understand the 
pros and cons of any prevention approach, but more can be done. The aim should therefore be to keep 
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improving and refining preventative efforts towards individual behaviour change as well as societal 
policies that address risk factors such as smoking and diet.  
Where should screening happen 
Doctors are increasingly familiar with a range of conditions linked to greater CV risk (such as 
hypertension, rheumatoid arthritis, systemic lupus erythematosus, erectile dysfunction, severe mental 
illness22) as well as those linked to diabetes risk (such as obesity, fatty liver, psoriasis, hypertension, 
gestational diabetes). Given the ease of adding non-fasting lipids, biochemistry and/or HbA1c 
(glycated haemoglobin, a test that captures average blood glucose levels over a few months) in all 
clinics then screening for CVD, diabetes and, where relevant, other outcomes such liver risk should 
not be an onerous process for clinicians in any speciality. Electronic records in many high income 
countries are now able to link hospitals to primary care records so it should be easy to check whether 
patients have had recent such tests in primary care; but if not, there is no reason why these tests 
cannot be added in those with a range of existing conditions known to be associated with higher 
cardiometabolic risks to give a more holistic assessment of a patient’s risk for cardiovascular disease 
and diabetes (Figure 1). Whether in the future, a unified risk scoring system that simultaneously 
calculates risks for subcategories of cardiovascular disease and other diseases rising in prevalence 
such as heart failure, is helpful requires investigation. In reality, in the era of rising comorbidity, we 
need more comprehensive risk scoring systems to enhance the push towards holistic medicine leading 
to tailored advice or choice of therapies as well as more cross-speciality training to improve the 
comprehensiveness of medical care. Notably, experts have already proposed setting up a new class of 
cardiometabolic specialists that have expertise across traditional boundaries23. 
 
Combining screening with lifestyle advice 
There have been widespread improvements in treating diseases such as cancers, cardiac and 
autoimmune disease once they are diagnosed or in recognising and treating risk factors such as blood 
pressure, cholesterol or glucose when they are significantly elevated. However, improvement in 
prevention (or even reversal) of disease via lifestyle changes has been lagging behind. Few 
individuals get formal assessment of their adiposity levels or ever asked about activity levels24, and 
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even fewer receive any sensible advice on how to address either. Furthermore, few doctors have any 
training in these areas25 and there is evidence that while patients think and say that they follow dietary 
advice, most do not. If truth be told, few doctors currently offer any dietary advice fearing to do so 
will take too much time and that most patients will fail to lose weight or will easily put it back on. 
This pattern needs to change if lifestyle is a major contributor to many chronic diseases including but 
not limited to diabetes, CVD, fatty liver disease, multiple cancers, renal disease, heart failure, some 
skin diseases like gout and psoriasis, as well as osteoarthritis and several lung conditions. What is less 
well understood is that whilst weight gain rapidly increases diabetes risks due to almost immediate 
increases in ectopic fat depots it may take longer, perhaps decades, for small to modest increases in 
weight to translate into cardiovascular outcomes, as adiposity takes time to accelerate atherosclerosis. 
The same may be true for other chronic diseases.  
 
Nevertheless, it is important to note that if better lifestyle advice helps some people improve their 
future weight trajectory (by slowing or ceasing weight gain or losing weight), this could have 
considerable benefits over the longer term by delaying or preventing a range of outcomes. In the 
reverse direction, weight loss can almost immediately lead to HbA1c reduction or indeed diabetes 
reversal26, whereas it may take years for small weight or lifestyle changes to show benefits on CVD 
outcomes27. This is one reason why any potential impact of obesity per se on population trends in 
CVD or other outcomes usually take time to emerge. That noted, we must not lose sight of the impact 
of even modest weight changes on quality of life, mental health and self-esteem; the health care 
profession is waking up to the importance of such "softer" patient reported outcomes, and nearly all 
overweight or obese patients are genuinely happy to discuss their weight28 and would wish to lose 
weight.   
 
Fortunately, there has been increase in recent understanding as to how to help people make 
sustainable lifestyle changes, particularly diet. We would argue that such new knowledge needs to be 
rapidly coalesced into something easily communicated to patients so that we start to give specific, 
actionable, evidenced-based advice that is consistent and easily digestible (Figure 2). It is also clear 
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we must do so in an empathetic manner so that patients understand we are there to help them and not 
to chastise or engage in any form of "fat-shaming". We believe the evidence now allows a range of 
options to be offered to patients from simple dietary changes to more intensive options. We also 
believe that such advice can be collated into a simple leaflet, an extension of the top ten tips concept29,  
directing patients to further evidence-based option. This range of options should include the potential 
for some to be referred to, or join a weight loss clinic30 as well as the option of low calorie diet31,32 for 
some or drugs for others to help aid or kick start weight loss. Of course, a minority of individuals may 
benefit from and progress to bariatric surgery or the emerging endobariatric techniques.  
 
Studying the approach 
Lifestyle trials are much harder than drug trials and this is why we have less robust evidence. The 
result is less emphasis on lifestyle in medical guidelines, whereas, if we could help many more make 
sustainable improvements in their lifestyle, the impact might be greater than we imagine. Recent trials 
showing the robust benefits of referring willing patients to commercial weight loss providers33, as 
well as low calorie diets (with initial total dietary replacement) in type 2 diabetes31, non-diabetes32, 
and psoriasis34, have provided new opportunities to test the impact of lifestyle on other diseases. 
There are ongoing trials of this approach in patients with atrial fibrillation35 and other areas such as 
liver disease. In a few years’ time, one might see trial evidence testing the potential benefits of more 
significant and sustainable weight loss in a range of other conditions (e.g. osteoarthritis, NASH, heart 
failure with preserved ejection fraction, sleep apnoea, resistant hypertension, post gestational 
diabetes) for which differential evidence levels exist for the benefits of weight loss. At the same time, 
more work is needed to better help people maintain weight loss after the initial period of dietary 
change. As the evidence base is improving, on the background of ever rising obesity, more research 
funds should be and appear to be, directed into prevention of disease than in treating it when it occurs. 
As noted before, the medical profession cannot directly alter the obesogenic environment, but we can 
offer a range of evidence-based lifestyle advice to our patients on how to lose weight sustainably or 
improve their weight trajectory.  
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Communicating advice 
There is clear evidence that increasing physical activity is associated with positive health outcomes, 
with any increase in activity being beneficial and more being better36. Importantly, building physical 
activity into the day, using approaches such as active travel37 or by incorporating multiple small 
amounts activity throughout the day can provide tangible benefits38. Pedometer-supported behaviour 
change approaches which incorporate setting of progressive physical activity goals, and provide self-
monitoring and feedback of activity levels are effective at increasing physical activity levels39, and 
there is emerging evidence that smartphone-based approaches can be effective for promoting physical 
activity40. However, it is important that targets are personalised and realistic – for example, for 
someone who is very inactive, initially increasing step count by 1000 per day, equivalent to about 10 
extra minutes of walking, can potentially provide benefit and provides a platform for further increases 
in activity with time. The amount of physical activity needed to substantially lower risk of adverse 
health outcomes may be relatively small. Data from a recent meta-analysis of the association between 
accelerometer-measured (rather than self-reported) physical activity in eight studies with over 
240,000 person-years of follow-up suggests that undertaking just 6 minutes per day of moderate-to-
vigorous physical activity was associated with a ~30% lower risk of mortality in maximally-adjusted 
models41, and in a randomised trial with >1100 participants aiming to increase physical activity and 
reduce sedentary time in overweight male soccer fans, we found that the intervention increased 
accelerometer-measured physical activity by ~6 minutes per day at 12 months, but this was sufficient 
to induce positive changes in biomarkers of cardiometabolic risk, including reducing insulin 
resistance by 15%42.  
 
Historically, there has been an emphasis on aerobic physical activities, typified by walking, in 
physical activity messaging, but there is now also increasing evidence that muscular strength and 
engaging in muscle strengthening exercise is likely to contribute to health-related outcomes. Data 
from the PURE study and UK Biobank show that low grip strength is strongly associated with risk of 
mortality (16-20% higher risk per 5 kg lower strength) and incidence of several chronic diseases43,44, 
and engaging in muscle-strengthening exercises appears to be associated with benefits over and above 
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aerobic activity for risk of mortality45,46. This is reflected in the recent UK guidelines on physical 
activity47 which have emphasised the importance of building and maintaining strength. We need to do 
more to equip healthcare professionals to deliver simple evidence-based interventions which include 
both muscular strength and aerobic activity at levels which are eminently more achievable than many 
people perceive.  
 
Conclusions 
With reductions in CVD death rates over the last few decades, but simultaneous rises in obesity and 
related conditions, metabolic disease is on the rise worldwide and beginning to be seen earlier in life. 
Obesity is also on the rise and a driver of comorbidity. Thus, it is time the medical profession 
develops better management protocols to help tackle this issue which has major impacts on patients' 
quality of life and future risks of disease – such work could in turn improve how lifestyle advice is 
delivered to the public. The important message is the need for the medical profession to develop a 
more empathetic and helpful approach to obesity so that patients feel encouraged to try to make 
changes in their lifestyle and better understand how to make these. Simple, specific, actionable, 
evidence-based advice is needed as well as an atmosphere that encourages people to try different 
options that have supporting evidence without the fear of being chastised if they do not succeed. At 
the same time, a parallel focus on preventing development of obesity in those at risk is needed, as well 
as more trials of meaningful weight loss as a treatment in a range of conditions. In addition, simple 
ways to assess CVD risk can be widened so all specialities can do this easily. There is no need for 
overnight fasting for blood testing and most people can accurately complete a simple risk score so all 
specialities can screen for CVD risk or indeed diabetes. Such screening can also be done or 
commenced in many locations outside of hospitals thereby encouraging more at risk and often harder 
to reach to be screened. We also need better tools to explain risks to the public in a way that 
incentivises them to engage with lifestyle better and, where relevant, to be understand the benefits of 
being more compliant with their preventative medications. In short, it is time to up our game on 
prevention with a more empathetic and helpful focus on lifestyle.  
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Figure legends 
 
Figure 1. Risk assessment for cardiometabolic disease. 
 
 
  
Risk scoring for CVD or diabetes could take place in a two-stage process. The first step would be 
non-laboratory based, requiring only blood pressure, weight and height along with specific questions. 
In those above a certain age, or shown to be at elevated risk for either or both of CVD and diabetes, 
then progression to measurement of lipids and HbA1c (or fasting glucose if appropriate) can be done 
easily in nearly all clinical settings. The key concepts are that the simultaneous assessment of risks for 
a range of condition is now possible but that further work is needed to determine how best to do this. 
Determining risks for several conditions may better motivate people to improve their lifestyles or, as 
recommended, comply with preventative medicines.  
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Figure 2. Simple, specific, actionable, evidence-based advice for individuals on lifestyle. 
 
  
The evidence base for approaches that result in diet improvement and activity increase in individuals 
has improved substantially in the last decade such that it may now be possible to give patients much 
simpler advice in a short leaflet of options (and extension of the 10 tips concept29) that is specific and 
more easily actioned.  By moving in this direction, we believe it is possible to substantially improve 
the routine “prescription” of lifestyle advice in all medical settings. This should lead, in turn, to more 
patients understanding how to achieve beneficial changes and adopting some, although clearly some 
individuals will require and only benefit from more intensive options. We also suggest a need for all 
such advice to be given in a much supportive and non-judgemental manner.  
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Box 1  
 
Options for Screening for cardiovascular disease, diabetes and liver disease:  
• Multiple risk scores for cardiovascular disease based on simple questions, physical measures 
and simple blood tests are now available online e.g. JBS3 in the UK 
[http://www.jbs3risk.com/] or the joint AHA/ACC score in the USA 
[ http://www.cvriskcalculator.com/]. Risk scoring need not be difficult, and can be repeated 
easily over time. 
• Measurements of circulating lipid levels which are needed for full cardiovascular risk scores, 
can be measured in the non-fasting state for CV risk factor scores and total and HDL-
cholesterol suffice for most purposes.  In low-income countries where blood tests are harder 
to obtain, the addition of body mass index48 and grip strength44 may aid risk scores. 
• Online diabetes risks are plentiful e.g. https://qdiabetes.org/ or 
http://riskscore.diabetes.org.uk/.  These can be done very quickly and help guide which 
people require formal blood testing for HbA1c or fasting glucose.  
• Multiple risk scores for liver fibrosis are now available online. Patients with low risk scores 
can be safely monitored in non-specialist setting. Patients with indeterminate and high-risk 
scores should be referred for further testing 
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Box 2  
Future questions/challenges with respect to cardio-metabolic risk screening  
• Is it possible and desirable to develop a risk algorithm which simultaneously reads out 10-
year and life time risks for diabetes, cardiovascular disease and its subcomponents and risk of 
mortality? Could such a risk algorithm usefully add risk for conditions such as heart failure or 
other conditions? 
• Can the presentation of all risk algorithms be improved so that people are better able to 
understand their risks, for example how they compare with others of their age, and how to 
mitigate them?  
• Would better explanations of risks motivate more people to adopt lifestyle changes that lessen 
risks and, if relevant, commence and adhere to preventative medications?   
• Can non-invasive risk assessments incorporating blood pressure and weight and height be 
safely expanded to pharmacies, work places, sports centres or other community settings to 
provide greater options to have an initial risk score for CVD outcomes and diabetes and to 
receive appropriate advice on lifestyle changes or to attend their primary care provider for 
further assessment?    
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